Entry of New Drugs and doctors' Prescriptions
This paper is about entry of new drugs in pharmaceutical markets. More specifically, I analyze the diffusion of new drugs among doctors. My empirical analysis uses non-parametric duration models, which are flexible enough to identify the most important covariates influencing the doctors' adoption decisions. My results peak to issues such as why generic drugs do not have large market shares in post-patent drug markets. When I analyze entry of bio-equivalent products, I find that the doctors' past dispersion across drugs in a therapeutic market is the best predictor of the likelihood of adoption. When a new presentation form is introduced by an incumbent firm, the doctors who extensively prescribed the brand in the other presentation forms are the ones most likely to adopt the new drug. Finally, I find that doctors are not firm-loyal in their prescribing behaviour across therapeutic markets.
|Date of creation:||Mar 1996|
|Date of revision:||Jan 1998|
|Contact details of provider:|| Postal: Egham Hill, Egham, Surrey, TW20 0EX, UK.|
Phone: +44 1784-414228
Fax: +44 1784-439534
Web page: http://www.rhul.ac.uk/economics/
|Order Information:|| Postal: Egham Hill, Egham, Surrey, TW20 0EX, UK.|
When requesting a correction, please mention this item's handle: RePEc:hol:holodi:9813. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Claire Blackman)The email address of this maintainer does not seem to be valid anymore. Please ask Claire Blackman to update the entry or send us the correct email address
If references are entirely missing, you can add them using this form.